Checkpoint Licenses Cancer Drugs from Teva

Biotech company Checkpoint Therapeutics has reached an agreement to license from Teva worldwide rights to develop and commercialize CEP-8983 and its small molecule prodrug.

The prodrug, CEP-9722, is designed for treatment of solid tumors and is a small molecule selective inhibitor of the PARP-1 and PARP-2 enzymes.  Checkpoint will develop the biologic as a monotherapy and in combination with other anti-cancer agents.

Financial terms of the agreement were not disclosed.